Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin memorial sloan-kettering cancer center experience from 1995 to 2009

International Journal of Gynecological Cancer

Volumn 23, Issue 5, 2013, Pages 929-934

  Makker, Vicky ^a,b   Hensley, Martee L ^a   Zhou, Qin ^a   Iasonos, Alexia ^a   Aghajanian, A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Memorial Sloan Kettering Cancer Center ^*  (United States)

Author keywords

Doxorubicin; Paclitaxel carboplatin; Recurrent endometrial carcinoma

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DYSPNEA; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; FLUSHING; FOLLOW UP; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTAL PAIN; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 84880434475     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182915c20     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Randall M, Filiaci V, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 2006;24:36-44.
3. Homesley H, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin or with or without paclitaxel: A GOG study. Gynecol Oncol. 2009;112:543-552.
4. Kiess AP, Damast S, Makker V, et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol. 2012;127:321-325.
5. Miller D, Filiaci V, Fleming G. et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study [abstract]. Gynecol Oncol. 2012;125:771-773.
6. Thigpen JT, Blessing JA, Lagasse LD, et al. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1984;7:253-256.
7. Garcia AA, Blessing JA, Nolte S et al. Gynecologic Oncology Group. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group. Gynecol Oncol. 2008;111:22-26.
8. Tait DL, Blessing JA, Hoffman JS, et al. A phase II study of gemcitabine (Gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol. 2011;121:118-121.
9. Sutton GP, Blessing JA, Homesley HD, et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer. 1994;73:1453-1455.
10. Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic oncology group trial 129-P. J Clin Oncol. 2009;27:3104-3108.
11. Fracasso PM, Blessing JA, Molpus KL, et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;103:523-526.
12. Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:277-281.
13. Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419-423.
14. Stewart CF, Ratain MJ. Topoisomerase interactive agents. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer. Philadelphia, PA: Lippincott-Raven, Inc; 1997:452-467.
15. Maluf, FC, Spriggs, D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol. 2002;85:18-31.
16. Horton J, Begg CB, Arseneault J, et al. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep. 1978;62:159-161.
17. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 1994;12:1408-1414.
18. Homesley HD, Blessing JA, Sorosky J, et al. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol. 2005;98:294-298.
19. Balbi G, Visconti S, Monteverde A, et al. Liposomal doxorubicin: A phase II trial. Acta Biomed. 2007;78:210-213.
20. Sutton GP, Blessing JA, DeMars LR, et al. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol. 1996;63:25-27.
21. Katsumata N, Noda K, Nozawa S, et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study. Br J Cancer. 2005;93:999-1004.
22. Homesley HD, Meltzer NP, Nieves L, et al. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. Int J Clin Oncol. 2008;13:62-65.
23. Di Legge A, Trivellizzi IN, Moruzzi MC, et al. Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer. Int J Gynecol Cancer. 2011;21:1446-1451.
24. Miller DS, Blessing JA, Drake RD, et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology. Gynecol Oncol. 2009;115:443-446.
25. Moore DH, Blessing JA, Dunton C, et al. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 1999;75:473-475.
26. Miller DS, Blessing JA, Lentz SS, et al. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol. 2002;87:247-251.